Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Pathogens and Global Health highlights current debate on counterfeit medicine

The latest issue of Pathogens and Global Health highlights the current debate surrounding the under-investigated, and politically sensitive, issue of counterfeit medicine. Issue 106.2 includes an interview with Dr Paul Newton, Head of the Laos arm of the Wellcome Trust's Major Overseas Programmes, and a number of articles highlighting the technological innovations and field initiatives that are challenging this threat to global health.

13 Sep 2012

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

The U.S. Food and Drug Administration today approved the production and use of Choline C 11 Injection, a Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.

13 Sep 2012

Zhejiang Hisun Pharmaceuticals, Pfizer launch new joint venture

Pfizer Inc., the world's largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals, a leading Chinese pharmaceutical company, today announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

13 Sep 2012

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Ampio Pharmaceuticals, Inc. (AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today that it has entered into a definitive agreement with Ethypharm Ltd for the manufacturing of Zertane, Ampio's drug for the treatment of premature ejaculation.

12 Sep 2012

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections.

11 Sep 2012

Polysaccharopeptide improves survival in dogs with hemangiosarcoma

Dogs with hemangiosarcoma that were treated with a compound derived from the Coriolus versicolor mushroom had the longest survival times ever reported for dogs with the disease.

11 Sep 2012

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

11 Sep 2012

Jazz Pharmaceuticals receives new U.S. patent for Xyrem oral solution

Jazz Pharmaceuticals plc. today announced that a new patent related to Xyrem (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today.

11 Sep 2012

MRI workers experience transient neurocognitive effects

Individuals working in the vicinity of magnetic resonance imaging machines may experience transient neurocognitive effects when moving their heads, research demonstrates.

10 Sep 2012

Akonni receives NSF's Phase 2 SBIR Grant to develop Lab-on-a-Film microarray

Akonni Biosystems, a life science tools / molecular diagnostics company that develops, manufactures, and plans to market molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $498,780 Phase 2 SBIR Grant from the National Science Foundation (NSF).

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Nordion third quarter revenue increases 0.5% to $67.1 million

Nordion Inc., a leading provider of products and services to the global health science market, today reported results for the fiscal third quarter ended July 31, 2012. The Company generated $67.1 million in revenue for the third quarter, an increase of $0.3 million, or 0.5%, over revenue of $66.8 million for the same period in 2011.

6 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

GE Healthcare introduces KUBio factory

GE Healthcare, the healthcare business of GE, today introduced KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

4 Sep 2012

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

Currently in the United States, there are over 1.5 million people living with Parkinson's and 50,000 new cases reported each year

30 Aug 2012

India's contribution to global health R&D needs domestic, international support

As the BRIC countries -- Brazil, Russia, India, and China -- invest more in innovations in health technologies and other areas, "many are looking to these countries to correct the global health research and development (R&D) imbalance that leaves the poor without needed products such as an improved tuberculosis (TB) vaccine or tests to help diagnose patients in remote rural settings," David de Ferranti, president of Results for Development Institute (R4D), writes in the Huffington Post Blog.

30 Aug 2012

Charles River announces acquisition of Accugenix

Charles River Laboratories International, Inc. announced today that it has acquired Accugenix, Inc., the premier global provider of cGMP-compliant contract microbial identification testing, for approximately $17 million in cash.

30 Aug 2012

Antibiotic residues in meat can allow pathogenic bacteria to proliferate

Antibiotic residues in uncured pepperoni or salami meat are potent enough to weaken helpful bacteria that processors add to acidify the sausage to make it safe for consumption, according to a study to be published in mBio-, the online open-access journal of the American Society for Microbiology, on August 28.

29 Aug 2012

New method simplifies pharmaceutical production of proteins

Engineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions, including diabetes, cancer, arthritis and macular degeneration.

29 Aug 2012

TaiMed, WuXi enter ibalizumab manufacturing agreement

WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.

29 Aug 2012